Save

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

PHASE3RECRUITING

A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).

Simpliy with AI

Study details:

The study consists of a screening period of 2 to 8 weeks and a 52-week randomized double-blind placebo-controlled treatment period. After completion of the treatment period, participants will be eligible to participate in an optional active treatment extension period (lasting for 24 weeks), followed by a 12-week off-treatment safety follow-up period. Participants who will not participate in the extension period will participate in a 12-week off-treatment safety follow-up period following completion of the 52-week treatment period.

This study will randomize approximately 360 participants. The participants will be randomized at 1:1:1 ratio to the 3 treatment arms.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Participant must be 12 to 80 years of age inclusive, at the time of signing the informed consent/assent.

Weight ≥ 40 kg at Visit 1

Established diagnosis of EoE with a previous EGD and esophageal biopsy confirming a diagnosis of EoE.

Participants who have symptomatic EoE as defined by a history of on average at least 2 episodes of dysphagia (any severity of food going down slowly or being stuck in the throat) per week in the 4 weeks prior to Visit 1.

Must remain on a stabilized diet for at least 8 weeks prior to Visit 1 and during the course of the study (stable diet is defined as no initiation of single or multiple elimination diets or reintroduction of previously eliminated food groups).

May be on any background PPI and/or STC, during the course of the study, as long as background medications have been stable for at least 8 weeks prior to the screening/run-in period (Visit 1) and there is agreement not to change background medication or dosage unless medically indicated, during the screening/run-in and treatment period.

Participants currently on leukotriene inhibitors and/or steroid treatments for asthma or allergies that are inhaled or administered intranasally, must report a stable dose for at least 4 weeks prior to the screening/run-in period (Visit 1).

If a medication for EoE (for example PPI and/or STC) is discontinued prior to the screening/run-in, there should be a washout period of at least 8 weeks prior to Visit 1. Discontinuation of any marketed biologic (monoclonal or polyclonal antibody) should have a washout period of 4 months or 5 half-lives prior to Visit 1, whichever is longer.

Participants should have previously documented standard of care treatment, which could include PPI and/or STC and/or diet.

Exclusion criteria

Other gastrointestinal disorders such as active Helicobacter pylori infection, history of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, celiac disease, eosinophilic enteritis, colitis, diverticulitis, irritable bowel syndrome, or other clinically significant gastrointestinal conditions as per Investigator discretion.

Esophageal stricture that prevents the easy passage of a standard endoscope or any critical esophageal stricture that requires dilation at screening.

Use of a feeding tube, or having a pattern of not eating solid food >3 days of week. Solid food is defined as food that requires chewing before swallowing.

Hypereosinophilic syndrome

EGPA vasculitis

Esophageal dilation performed within 8 weeks prior to screening.

Simplify with AI

Eligibility

Age eligible for study : 12 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2022-11-10

Primary completion: 2026-05-01

Study completion finish: 2027-01-08

Study type

TREATMENT

Phase

PHASE3

Trial ID

NCT05583227

Intervention or treatment

BIOLOGICAL: Tezepelumab

OTHER: Placebo

Conditions

• Eosinophilic Esophagitis

Image related to Eosinophilic Esophagitis

Condition: Eosinophilic Esophagitis
BIOLOGICAL: Tezepelumab and other drugs
Elizabeth Vale, Not Specified, Australia and more
Sponsor: AstraZeneca

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Research Site

Research sites nearby

Select from list below to view details:

Research Site
Elizabeth Vale, Not Specified, Australia
Research Site
Kogarah, Not Specified, Australia
Research Site
Mitcham, Not Specified, Australia
Research Site
South Brisbane, Not Specified, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Tezepelumab Low Dose Tezepelumab subcutaneous injections, in accessorised pre-filled syringes	BIOLOGICAL: Tezepelumab Tezepelumab subcutaneous injection
EXPERIMENTAL: Tezepelumab High Dose Tezepelumab subcutaneous injections, in accessorised pre-filled syringes	BIOLOGICAL: Tezepelumab Tezepelumab subcutaneous injection
PLACEBO_COMPARATOR: Placebo Placebo subcutaneous injections, in accessorised pre-filled syringes	OTHER: Placebo Placebo subcutaneous injection

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels	Peak esophageal eosinophil count per HPF determined by histological analysis of 2-4 biopsies from each of the proximal, mid, and distal esophagus.	Week 24
Change from baseline in DSQ (Dysphagia Symptom Questionnaire) score	The Dysphagia Symptom Questionnaire (DSQ) captures the presence and severity of dysphagia symptoms in the past day in a 4-item questionnaire. The DSQ score is calculated over 14-day periods and ranges from 0 to 84, with a lower score indicating less severe dysphagia.	Week 24

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Change from baseline in EoE EREFS (Endoscopic reference score )	The EoE EREFS is a scoring system for assessing the presence and severity of the major endoscopic signs of EoE, including esophageal edema, rings, exudates, furrows, and stricture. EoE endoscopic appearances will be analyzed by the EoE-EREFS, a scoring system for inflammatory and fibrostenotic features of the disease. Proximal and distal esophageal areas will be scored, with the score for each region ranging from 0 to 9, and the overall score ranging from 0 to 18. Higher scores indicate more extensive disease.	Week 24, Week 52
Change from baseline in EoE-HSS (Histologic scoring system) grade score	EoE HSS is a histology scoring system for esophageal biopsies that evaluates 8 features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities are scored using a 4-point scale (0 normal; 3 maximum change).	Week 24
Change from baseline in EoE-HSS (Histologic scoring system) stage score	EoE HSS is a histology scoring system for esophageal biopsies that evaluates 8 features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities are scored using a 4-point scale (0 normal; 3 maximum change).	Week 24
Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels	The peak esophageal eosinophil count is based on 2-4 esophageal biopsies from 2-3 locations.	Week 52
Change from baseline in DSQ (Dysphagia Symptom Questionnaire) score	The Dysphagia Symptom Questionnaire (DSQ) captures the presence and severity of dysphagia symptoms in the past day in a 4-item questionnaire. The DSQ score is calculated over 14-day periods and ranges from 0 to 84, with a lower score indicating less severe dysphagia.	Week 52
Response of achieving clinico-histological remission	Achieving pre-determined histologic and symptomatic remission thresholds.	Week 24, Week 52

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis